Paul Jäger, Benno Biermann, Nora Liebers, Felicitas Schulz, Ben-Niklas Baermann, Sören Twarock, Stefanie Geyh, Kathrin Nachtkamp, Patrick Tressin, Annika Kasprzak, Felix Matkey, Titus Watrin, Malika El Yaouti, Ulrich Germing, Sascha Dietrich, Guido Kobbe
{"title":"单倍体同种异体干细胞移植作为错配供体患者的优越选择- 152例患者的单中心经验","authors":"Paul Jäger, Benno Biermann, Nora Liebers, Felicitas Schulz, Ben-Niklas Baermann, Sören Twarock, Stefanie Geyh, Kathrin Nachtkamp, Patrick Tressin, Annika Kasprzak, Felix Matkey, Titus Watrin, Malika El Yaouti, Ulrich Germing, Sascha Dietrich, Guido Kobbe","doi":"10.1002/jha2.70012","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In a cohort of 152 patients undergoing allo-SCT from 2012 to 2023, haploidentical donors with post-transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others.</p>\n </section>\n \n <section>\n \n <h3> Clinical trial registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70012","citationCount":"0","resultStr":"{\"title\":\"Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients\",\"authors\":\"Paul Jäger, Benno Biermann, Nora Liebers, Felicitas Schulz, Ben-Niklas Baermann, Sören Twarock, Stefanie Geyh, Kathrin Nachtkamp, Patrick Tressin, Annika Kasprzak, Felix Matkey, Titus Watrin, Malika El Yaouti, Ulrich Germing, Sascha Dietrich, Guido Kobbe\",\"doi\":\"10.1002/jha2.70012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In a cohort of 152 patients undergoing allo-SCT from 2012 to 2023, haploidentical donors with post-transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Clinical trial registration</h3>\\n \\n <p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\\n </section>\\n </div>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"6 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70012\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients
Background
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes.
Results
In a cohort of 152 patients undergoing allo-SCT from 2012 to 2023, haploidentical donors with post-transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes.
Conclusion
These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others.
Clinical trial registration
The authors have confirmed clinical trial registration is not needed for this submission.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
